You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明康德(02359.HK)认购200万美元基金份额重点投资生命科学
格隆汇 08-22 17:13

格隆汇8月22日丨药明康德(02359.HK)公告,2019年8月21日,公司全资子企业WuXi Pharma Tech Healthcare Fund IL.P.与Mission BayCapital III,L.P.签署Subscription Agreement,约定由WuXi FundI认缴200万美元的投资基金份额,占已募集投资基金份额的3.3%。

截至本公告日,WuXi FundI尚未实缴出资,后续WuXiFundI将以自有资金根据认购协议及普通合伙人的出资要求履行出资义务。

投资基金预计募集总额不超过8,500万美元,WuXi FundI本次认缴200万美元后,投资基金已募集60,606,060美元。投资基金将专注于投资生命科学领域涉及治疗产品、诊断产品、合成生物学和研究工具的新创企业。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account